Navigation Links
GlySure Secures $10.9 Million in Series C Financing Round
Date:1/9/2012

OXFORD, England, January 9, 2012 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced the close of its $10.9 million Series C financing round. GlySure will use this funding to complete clinical trials to supportregulatory approval in the United States and Europe.

The financing round was supported by Morningside Venture, as well as existing investors Amadeus Capital Partners, Chester Investments and Delta Partners. Since its foundation in May 2006, GlySure has secured a total of $19.5 million in venture capital funding.

"We are excited about the opportunity to support GlySure's regulatory trials," said Reenie McCarthy, representing Morningside Venture. "There is a significant unmet need for continuous glucose monitoring in critical care, and the results from GlySure's initial ICU trials show that the company is on track to deliver the performance and ease-of-use required to enable clinicians to effectively implement Tight Glycemic Control."

GlySure recently completed initialhuman use trials on over 90 intensive care patients. The trials demonstrated that the GlySure system can accurately measure blood glucose levels across the entire human physiological range for the duration of a patient's stay in the Intensive Care Unit(ICU).

"This new financing round recognizes not only the significant clinical results, but also the management team's capital efficiency and ability to cost effectively deliver a product with the potential to improve outcomes for over 8 million ICU patients annually," added Dr. Joey Mason, partner at Delta Partners and a director of GlySure.

"There have been over 100 publications demonstrating the ability of Tight Glycemic Control to improve outcomes and reduce cost in the ICU," said Chris Jones, GlySure CEO. "We are grateful for the support of our existing and new investors and look forward to completing our regulatory trials so that we can
'/>"/>

SOURCE GlySure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
3. GeoVax Secures $10 Million Financing Commitment
4. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
5. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
6. ALung Secures $2.5 Million
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. EnzySurge, Maker of DermaStream(R) Secures US$2.5 Million in Private Capital
9. HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing
10. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
11. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... that controls when genes are switched on or off ... brain to regulate metabolism, UT Southwestern Medical Center researchers ... therapies to treat obesity and diabetes, since the transcription ... appears to influence the body,s sensitivity to insulin ... to the body,s regulation of food intake and sugar ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) today unveiled branding ... annual patient and family conference in Chicago. , “This ... as we – the first and now only national ... brain tumor research – extend our reach by engaging ... getting our materials and services into the hands of ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Progress in ... in a new era of promising brain tumor treatments, ... Medical School, director of the Center for Neuro-Oncology, Dana-Farber ... (ABTA) annual Patient and Family Conference in Chicago, July ... science and new technology are impacting the development of ...
(Date:7/25/2014)... Splashtop, Inc. announced that it has ... Business and Splashtop Enterprise will now be featured in ... MaaS360 WorkPlace SDK to enable enterprise-grade security controls for ... Enterprise offer secure remote access, support, and colloaboration for ... ease of use, collaborative features, and support for both ...
(Date:7/25/2014)... Garth Brooks Chicago tickets go on sale Friday, July ... Garth Brooks was one of the leaders on the country music ... Since "Much Too Young (To Feel This Damn Old)" was released, ... native and in the years that he has been away from ... and in the recording studio. Between 2001 and 2009, fans heard ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3
... Robotic Urology Symposium+2011 will take place Jan. 13-16, 2011 ... numerous 3D and 2D surgeries (each morning), observing differences ... United States and abroad. , Lectures and plenary sessions ... as well as alternatives therapies to treat patients with ...
... receiving the appropriate training and support they need to help ... and inadequate levels of care. Those are the key ... specialists from the University of Nottingham, UK, and published in ... Mental Health Nursing. Staff nurse Jo McHale and ...
... About ten years ago, the discovery of microRNAs ― ... unlocked a world of scientific possibilities, including a deeper ... "deep sequencing," which gives scientists the ability to discover ... Now, Tel Aviv University researchers have developed the cutting-edge ...
... whose partners have breast cancer are at increased risk of ... hospitalization. Published early online in Cancer , a peer-reviewed ... clinicians should address the mental health of cancer patients, loved ... not only affected patients but of their closest relatives as ...
... By Steven Reinberg HealthDay Reporter , ... United States are not drinking as much water as ... a new study suggests. "Even mild dehydration can ... and dry mouth," said Samantha Heller, clinical nutrition coordinator ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Sept. 24 ... diseases on the planet, and the second leading cause of ... slowly conquering cancer, according to an assessment of cancer trends ... the U.S. Centers for Disease Control and Prevention, the American ...
Cached Medicine News:Health News:Medical profession needs special training to handle self-harm, says international review 2Health News:Medical profession needs special training to handle self-harm, says international review 3Health News:Diving deeper into the gene pool 2Health News:Partners of breast cancer patients are at risk of developing mood disorders 2Health News:U.S. Kids Drink Too Little Water: Study 2Health News:U.S. Kids Drink Too Little Water: Study 3Health News:As Science Unlocks Secrets, Cancer Rates Fall 2Health News:As Science Unlocks Secrets, Cancer Rates Fall 3Health News:As Science Unlocks Secrets, Cancer Rates Fall 4
... ophthalmic solution is an anti-infective ... doctor may instruct you to ... eye infection caused by bacteria. ... are the 2 types of ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: